Korean J Urol.
2004 May;45(5):456-462.
Tumor-specific Gene Therapy for Renal Cell Carcinoma Using MN/CA9-directed Replication-competent Adenovirus
- Affiliations
-
- 1Department of Urology, Ajou University School of Medicine, Suwon, Korea.
- 2Department of Medical Oncology, Ajou University School of Medicine, Suwon, Korea.
- 3Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.
- 4Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Abstract
-
PURPOSE: A new therapeutic approach is needed in patients with metastatic renal cell carcinoma (RCC) because of a dismal prognosis. MN/CA9 is a transmembrane glycoprotein that was first identified in the human cervical carcinoma cell line, HeLa. Since MN/CA9 protein is highly expressed in RCC tissues, but not in normal kidney, we constructed a tumor-specific replication-competent adenoviral vector utilizing MN/CA9 promoter (Ad-MN/CA9-E1a) and demonstrated its selective cytotoxicity toward MN/CA9-expressing RCC cells in vitro.
MATERIALS AND METHODS
MN/CA9-positive (HeLa, SK-RC-52) and MN/ CA9-negative (SK-RC-29) cells were used. RT-PCR assay for MN/CA9 mRNA was performed in each cells. Ad5 E1a protein production in each cells after infection with Ad-MN/CA9-E1a was determined by western blot analysis. In vitro cytotoxicity assay was performed for assessing the selective cytotoxicity of Ad-MN/CA9-E1a to MN/CA9-expressing cells.
RESULTS
RT-PCR assay showed that a distinct 255-bp fragment corresponding to the sequence within MN/CA9 cDNA was detected in HeLa and SK-RC-52 cells, but SK-RC-29 cells did not have MN/CA9 transcripts. Western blot analysis demonstrated that HeLa and SK-RC-52 cells showed much stronger Ad5 E1a protein expressions compared with SK-RC-29. In vitro cytotoxicity assay revealed that the growth of MN/CA9-positive cells was significantly inhibited with 0.1-1MOI of Ad-MN/CA9-E1a, but the growth of MN/CA9-negative cells (SK-RC-29) could only be inhibited by as many as 100MOI.
CONCLUSIONS
These results suggest that a novel replication-competent adenoviral vector mediated by MN/CA9 promoter, Ad-MN/CA9-E1a, can selectively replicate in MN/CA9-expressing cancer cells with cytotoxic effects and may be utilized for the treatment of RCC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT)
- Enhanced Oncolytic Effect and Anti-Tumor Effect of Replication Competent Adenovirus with Double Mutation in E1A & E1B Regions
- Development of a packaging cell line for propagation of replication-deficient adenovirus vector
- Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein
- Evaluation of E1B-mutant Replicating Adenoviruses for Cancer Gene Therapy
